Advertisement

Advertisement

DE:S2L Stock Latest News

Bausch + Lomb price target raised to $17 from $16 at Evercore ISI

The FlyBausch + Lomb price target raised to $17 from $16 at Evercore ISI

Bausch + Lomb announces new findings from third State of Dry Eye survey

PremiumThe Fly

Bausch + Lomb announces new findings from third State of Dry Eye survey

6d ago

Bausch + Lomb Shareholders Back Board and Executive Pay

PremiumCompany Announcements

Bausch + Lomb Shareholders Back Board and Executive Pay

2M ago

Bausch + Lomb announces U.S. launch of PreserVision AREDS3

PremiumThe Fly

Bausch + Lomb announces U.S. launch of PreserVision AREDS3

2M ago

Bausch + Lomb launches Bi-Blade+ dual-port vitrectomy cutter in Europe

PremiumThe Fly

Bausch + Lomb launches Bi-Blade+ dual-port vitrectomy cutter in Europe

2M ago

Bausch + Lomb Lifts Outlook After Margin-Heavy Quarter

PremiumCompany AnnouncementsBausch + Lomb Lifts Outlook After Margin-Heavy Quarter

2M ago

Bausch + Lomb price target lowered to $16 from $17 at Evercore ISI

The Fly

Bausch + Lomb price target lowered to $16 from $17 at Evercore ISI

2M ago

Bausch + Lomb price target lowered to $16 from $18 at Deutsche Bank

The Fly

Bausch + Lomb price target lowered to $16 from $18 at Deutsche Bank

2M ago

Bausch + Lomb price target lowered to C$19 from C$21 at Citi

PremiumThe Fly

Bausch + Lomb price target lowered to C$19 from C$21 at Citi

2M ago

Bausch + Lomb: Solid Q1 Beat and Pharma Momentum Offset by Spin-Off Uncertainty, Supporting Hold Rating

PremiumRatings

Bausch + Lomb: Solid Q1 Beat and Pharma Momentum Offset by Spin-Off Uncertainty, Supporting Hold Rating

2M ago

Bausch + Lomb reports Q1 adjusted EPS 5c, consensus 5c

PremiumThe Fly

Bausch + Lomb reports Q1 adjusted EPS 5c, consensus 5c

2M ago

Bausch + Lomb raises FY26 revenue view to $5.420B-$5.530B from $5.375B-$5.475B

PremiumThe Fly

Bausch + Lomb raises FY26 revenue view to $5.420B-$5.530B from $5.375B-$5.475B

2M ago

Bausch + Lomb announces narrative review on certain B vitamins

PremiumThe FlyBausch + Lomb announces narrative review on certain B vitamins

3M ago

Bausch + Lomb reports nearly 725k lbs. of eye care materials recycled

The Fly

Bausch + Lomb reports nearly 725k lbs. of eye care materials recycled

3M ago

Bausch + Lomb Wins FDA Clearance for Next-Generation Vitrectomy Cutter and Fluidics Upgrade

Company Announcements

Bausch + Lomb Wins FDA Clearance for Next-Generation Vitrectomy Cutter and Fluidics Upgrade

3M ago

Bausch + Lomb receives FDA 510k clearance for Bi-Blade+

PremiumThe Fly

Bausch + Lomb receives FDA 510k clearance for Bi-Blade+

3M ago

Bausch + Lomb Rolls Out enVista Envy Premium Intraocular Lens Across Europe

PremiumCompany Announcements

Bausch + Lomb Rolls Out enVista Envy Premium Intraocular Lens Across Europe

3M ago

Bausch + Lomb announces European availability of enVista Envy lenses

PremiumThe Fly

Bausch + Lomb announces European availability of enVista Envy lenses

3M ago

Bausch + Lomb to Unveil Broad New Ophthalmic Data at ASCRS Meeting

PremiumCompany Announcements

Bausch + Lomb to Unveil Broad New Ophthalmic Data at ASCRS Meeting

3M ago

Bausch + Lomb price target lowered to $17 from $17.50 at Evercore ISI

PremiumThe FlyBausch + Lomb price target lowered to $17 from $17.50 at Evercore ISI

3M ago

Bausch + Lomb Sets Date for First-Quarter 2026 Results and Investor Call

Company Announcements

Bausch + Lomb Sets Date for First-Quarter 2026 Results and Investor Call

3M ago

Bausch + Lomb’s ELIOS Glaucoma System Hits Key Efficacy Marks in 24‑Month U.S. Trial

Company Announcements

Bausch + Lomb’s ELIOS Glaucoma System Hits Key Efficacy Marks in 24‑Month U.S. Trial

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >